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Abstract
Objective—To estimate the optimal age to pursue elective oocyte cryopreservation.
Design—A decision tree model was constructed to determine the success and cost-effectiveness 
of oocyte preservation versus no action when considered at ages 25 to 40 years, assuming an 
attempt at procreation 3, 5, or 7 years after initial decision.
Setting—A hypothetical decision analysis model.
Patients—Hypothetical patients between 25 and 40 years old presenting to discuss elective 
oocyte cryopreservation.
Intervention(s)—Decision to cryopreserve oocytes between age 25 and 40 versus taking no 
action.
Main Outcome(s) and Measures—Probability of live birth after initial decision whether or 
not to cryopreserve oocytes.
Results—Oocyte cryopreservation provided the greatest improvement in probability of live birth 
compared to no action (51.6% vs. 21.9%) when performed at age 37. The highest probability of 
live birth was seen when oocyte cryopreservation was performed at ages younger than 34 (>74%), 
although little benefit over no action was seen at ages 25–30 (2.6%–7.1% increase). Oocyte 
cryopreservation was most cost-effective at age 37 at $28,759 per each additional live birth in the 
oocyte cryopreservation group. When the probability of marriage was included, oocyte 
cryopreservation resulted in little improvement in live birth rates.
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Conclusion—Oocyte cryopreservation can be of great benefit to specific women and has the 
highest chance of success when performed at an earlier age. At age 37, oocyte cryopreservation 
has the largest benefit over no action and is most cost effective.
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INTRODUCTION
Over the past several decades the average age of a women’s first birth has increased to an 
all-time high of 25.6 years (1). In 2006, 1 in 12 women had their first birth at age 25 or 
older, compared to only 1 in 100 in 1970 (2). The cause of the delay in childbearing in 
western societies is thought to be multifactorial, stemming from both social and economic 
factors (3). In the United States the age of first marriage has increased since 1950, and in 
2009 the mean age of first marriage was 26 years for women (4). The delay in attempted 
childbearing comes at the cost of an increase in age-related infertility (5).
Standard fertility treatments can only partially overcome the fertility decline associated with 
aging (6). However, oocyte cryopreservation (OC) can be used as a method of fertility 
preservation for single women who are not ready to conceive. OC “freezes-in-time” oocyte 
quality, protecting the higher pregnancy rates associated with the use of younger oocytes (7). 
Oocyte cryopreservation has been shown to achieve live birth rates consistent with those of 
fresh oocytes in egg donation cycles (8). While there have been few studies on live birth 
rates after OC for fertility preservation, existing literature suggests that the technique is a 
viable option (9). Recently, committee statements concluded that the use of cryopreserved 
oocytes is no longer experimental (10) and that “oocyte cryopreservation to improve 
prospects of future child bearing … should be available for non-medical reasons” (11). 
Following these statements, two of the countries largest technology firms, Apple Inc. and 
Facebook Inc. announced they will provide a $20,000 employee benefit to fund OC 
(www.washingtonpost.com, accessed Oct. 15th, 2014).
Oocyte cryopreservation may offer a viable option for single women wanting to protect 
against the age-related decline in fertility. However, women and clinicians are now faced 
with several questions regarding its utilization. What is the live birth rate following OC for 
an individual woman? For a given women, to what extent does OC increase the probability 
of having a baby? At what age should oocytes be cryopreserved? What is the financial cost 
of banking eggs that may never be used?
The aim of this study was to use decision tree analysis to determine the benefit of OC, in 
terms of probability of future live birth; dependent on the age of the woman at the time of 
cryopreservation and intended wait time to pursuing pregnancy. A secondary aim was to 
determine the cost-effectiveness of OC.
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A decision analysis model was constructed (TreeAge Pro 1.0.2, Williamstown, MA) to 
determine the live birth rate (LBR) and cost-effectiveness when choosing to cryopreserve 
oocytes for elective fertility preservation compared to taking no action and in the future 
undergoing unassisted conception attempts for 6 months followed by traditional IVF (see 
Figure 1 for simplified model). The model mimics the logical progression of a single woman 
from the time she makes a decision about OC for social indications (Decision Age) to 
attempting conception 3, 5, or 7 years later (Horizon Ages). The model was run at each 
Decision Age from ages 25 to 40, allowing for an age-based estimate of the LBR and of the 
cost-per live birth. This study was considered exempt by the University of North Carolina 
IRB.
Some women will only attempt pregnancy after marrying, while others will conceive out of 
wedlock or use anonymous donor sperm. For this reason, we developed two models. In 
Model A, we assumed that a woman will only attempt to conceive after marriage and 
included the probability of marriage by the Horizon Age in the decision tree. Model B 
assumed that all women would attempt pregnancy at the Horizon Age regardless of marital 
status (with a spouse, partner, or donor sperm).
The tree accounted for the following probabilities: [1] marrying a male by the Horizon Age 
(Model A only); [2] unassisted conception after 6 months of attempts at Horizon Age; [3] 
miscarriage (if pregnancy resulted in miscarriage, unassisted conception was attempted for 
an additional 6 months); [4] LBR using oocytes cryopreserved at Decision Age (IVF-OC); 
[5] LBR with traditional IVF (IVF-T) at Horizon Age; [6] a 2nd or 3rd IVF-OC cycle and 
LBRs from these cycles; or [7] a 1st or 2nd frozen embryo cycle (FET) and LBR from these 
cycles.
Base-case probability data (i.e. probability of a specific event taking place) was compiled 
from multiple sources including national registries and surveys, ongoing research studies, 
and medical records from a large national network of infertility practices (IntegraMed) 
(Table 1). For women ages 25–40, the probability of marriage prior to the Horizon Age was 
calculated from the National Survey of Family Growth (Supplemental Figure 1a (7-year 
Horizon shown)) (12). The data for unassisted conception rates after 6 months was derived 
from 626 women enrolled in an ongoing time-to-pregnancy study, Time to Conceive, as 
previously described (Supplemental Figure 1b (7-year Horizon shown)) (13). After 
unassisted conceptions, the age-based LBR versus miscarriage was estimated from a large 
prospective national register linkage study of over 1.2 million pregnancies in Denmark 
(Supplemental Figure 1c (7-year Horizon shown)) (14). We assumed that all women who 
have not achieved live birth by natural methods will be diagnosed as infertile and will 
proceed with at least one IVF-OC or one IVF-T cycle, depending on the strategy chosen at 
Decision Age. For women who did not cryopreserve oocytes, LBR after IVF-T were 
calculated based on her Horizon Age using the 2011 CDC ART National Summary Report, 
which includes outcome data from 101,213 fresh, non-donor IVF cycles from 451 centers in 
the United States (Supplemental Figure 1d (7-year Horizon shown)) (15). For women who 
decided to freeze oocytes, but failed to conceive naturally and were thus infertile, we 
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derived LBR for IVF-OC cycles from the same CDC ART data, but used her ‘Decision Age’ 
(as opposed to Horizon Age) to estimate LBR (Supplemental Figure 1e (7-year Horizon 
shown)).
The probability of a 2nd or 3rd IVF-OC cycle was calculated from the IntegraMed system 
database. The number of metaphase II (MII) oocytes, by female age, from 33,821 IVF 
cycles performed between 2003–2013 in women with the diagnosis of male or tubal factor 
infertility was used to estimate the number of oocytes available for cryopreservation at the 
Decision Age. Patients who underwent oocyte retrieval for male or tubal factor infertility 
were presumed to have an oocyte yield similar to age matched women undergoing retrieval 
for elective oocyte cryopreservation. To determine the probability of a 2nd or 3rd IVF-OC 
cycles (if no live birth had occurred) we assumed that women with ≤ 8 oocytes were eligible 
for only 1 cycle, women with 8–16 oocytes would pursue a second IVF-OC, and women 
with ≥ 17 oocytes were eligible for a third IVF-OC (Supplemental Figure 1f (7-year Horizon 
shown)).
For those in the IVF-T branch who did not conceive after the fresh IVF cycle, we used the 
IntegraMed database to determine the probability of having supernumery embryos for a 1st 
and 2nd FET. Data about the number of embryos frozen from 35,279 IVF cycles for all ages 
between 25 and 46 in women with tubal or male factor infertility was compiled. The number 
of embryos to transfer per FET were based on “unfavorable criteria” from the 2012 ASRM 
committee opinion; this allowed us to estimate the probability of 0, 1, or 2 FET for all ages 
between 25 and 40 (Supplemental Figure 1g (7-year Horizon shown)) (16). The LBR for the 
1st and 2nd FET were assumed to be equivalent to IVF-T at the age of retrieval (horizon age) 
based on CDC ART 2011 reporting data (15).
Charges were interpreted from a societal prospective and adjusted to 2014 dollars using a 
using the Consumer Price Index (www.bls.gov/data/CPI) (17–20). Direct charges including 
costs of medications, laboratory costs and medical services including procedures were 
included in the model (Table 1). Indirect costs, such as loss of productivity were not 
included in the calculations. Additionally, to simplify the model, costs associated with 
pregnancy outcomes such as cost of miscarriage, preterm delivery, or twin/higher order 
multiple pregnancy are not included.
Prior to analyzing the models, we determined that an increase in LBR of 10% was clinically 
significant. This was consistent with power calculations of large randomized controlled 
trials studying interventions in IVF (21). An overall probability of live birth of >70% was 
considered excellent.
To assess the robustness of the models and account for error in probability and cost 
estimates, we utilized a one-way sensitivity analyses on all variables. We performed this 
analysis only for the Decision Ages with the largest difference in LBR and the lowest 
incremental cost-effectiveness ratio (ICER). The ICER is the ratio of overall difference in 
cost between choosing OC versus not choosing OC divided by the incremental increase in 
live birth ((ICER=CostOC − CostNo OC)/(Probality Live BirthOC − Probality 
Live BirthNo OC)), this can also be interpreted as the cost per additional live birth when 
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performing OC. When a precise range of cost or probability was not known from the 
literature, a 50% range of the base-case value was assumed. All variables in the decision 
model were analyzed independently.
RESULTS
In Model A, accounting for the probability of marriage, the greatest difference in probability 
of live birth with OC was 5.6% at age 35 (14.7% vs. 9.1%) with a 7-year horizon. In this 
model LBR never surpassed the predetermined threshold of an increase of 10%. The highest 
probability of live birth was seen when oocyte cryopreservation was performed at ages 25–
30 (53.5%-32.3%), although the increase in LBR over expectant management was very 
small (<3%). Both scenarios approached a 0% probability of live birth at age 40, due to the 
small chance of marriage within 7 years (16%) combined with poor IVF LBR (17.5%) in the 
oocyte cryopreservation group and low likelihood of achieving pregnancy with autologous 
oocytes by any means at age 47 (<1%) (Figure 2, Supplemental Table 1). The benefit of OC 
in terms of probability of LBR was further diminished with a 3- or 5-year horizon 
(Supplemental Figure 2).
In Model A, oocyte cryopreservation was most cost-effective, although still substantially 
higher in cost than electing to not cryopreserve oocytes, at age 35 with a 7-year horizon. At 
this age and horizon, the average projected cost of electing the OC arm was $12,910 per 
individual, while only $2,111 in the no action arm. The societal cost for each additional live 
birth (ICER) in the oocyte cryopreservation group was $196,032. Oocyte cryopreservation 
was least cost-effective between ages 25–30 with an ICER of $366,824–$698,722 (Figure 3, 
Supplemental Table 1).
For Model B (women will proceed with pregnancy attempts regardless of marital status, 
using donor sperm if necessary) starkly different results were obtained. In this model, at the 
7-year horizon, the greatest difference in the probability of live birth was 29.7% at a 
Decision Age of 37 (51.6% LBR for OC vs. 21.9% LBR for ‘no action’). The difference in 
LBR was greater than the predetermined threshold value of 10% for Decision Ages over 30. 
The probability of live birth was excellent (>70%) if OC was performed prior to age 34, 
with a gradual decrease in LBR until a low of 26.2% if performed after age 40 (Figure 2, 
Supplemental Table S1). The benefit of OC in terms of improved LBR is decreased with 3- 
and 5-year horizons (Supplemental Figure 1).
In Model B, OC was most cost-effective at age 37 with a 7-year horizon. The average 
projected cost at this age was $19,493 when OC was performed and $10,943 when no action 
was taken. The ICER in this scenario was $28,759. Once again, oocyte cryopreservation was 
least cost-effective when performed at younger ages with maximum ICER of $406,508 at 
age 25 (Figure 3, Supplemental Table 1).
A one-way sensitivity analysis was performed using Decision Ages and Horizon at which 
the greatest increase in probability of pregnancy and lowest cost-per additional live birth in 
both models was observed (35 yo for Model A and 37 yo for Model B, 7-year Horizon). 
When adjusting individual variables over ranges of cost or probabilities, there were no 
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instances in Model A where OC was a cost-saving modality (Supplemental Table 2). In 
Model B, the strategy to cryopreserve oocytes was more cost-effective when the cost of IVF 
exceeded $23,862. Adjusting the cost and probability of other variables had no effect on cost 
dominance (Supplemental Table 2).
DISCUSSION
We have developed an analytic model to estimate the utility and timing of fertility 
preservation with oocyte cryopreservation for elective indications. The results of the 
decision tree analysis suggest the largest improvement in LBR is seen when women are 
accepting of attempting pregnancy regardless of the sperm source (husband sperm, partner 
sperm, or donor sperm). The LBR was highest in both models when OC was performed at a 
younger age. However, the absolute benefit of OC over electing not to cryopreserve oocytes 
was small (<10%) at ages less than 32 years in both models. When marriage rates were 
considered (Model A), the absolute benefit of OC over electing not to cryopreserve oocytes 
was never greater than 10%. The largest improvement in LBR of 29.7% is seen in Model B 
at age 37 with a 7-year horizon; however at this age, the LBR is relatively low with both 
strategies (51.6% LBR with OC versus 21.9% LBR with no action). Using base-case costs 
and probabilities, OC was never a cost saving modality; the lowest cost-per additional live 
birth was $28,759 at age 37 (7-year Horizon) when marriage rates were not considered.
In order to account for differences in social practices relating to family building, separate 
models were created. In Model A, only women who married, attempted pregnancy. While 
we recognize that this assumption is not appropriate for all women, some single women, 
who are considering OC, anticipate using these oocytes only following partnering and are 
not willing to use donor sperm. For these women, Model A results are most appropriate. In 
this scenario, due to relatively low chances of finding a spouse, the overall LBR is severely 
limited; there is only a small increase in LBR with OC over taking no action. Because of 
this, the cost of gaining one additional live birth by OC is very large across all ages. The 
decreased LBR and high ICER is the direct result of the low probability of marriage.
Prior studies of the utility of OC for fertility preservation have not considered marriage rates 
(22–24). The National Survey of Family Growth (2006–2010) is a survey representative of 
the US population, encompassing multiple socio-economic levels and geographic regions. 
The probability of marrying later in life is higher in women with a bachelor’s degree 
compared to those without a college degree (25). Assuming 1) college education is a 
surrogate for socio-economic status and 2) only women with disposable income can 
consider oocyte cryopreservation given its high initial cost, Model A may slightly 
underestimate the LBR with both OC and ‘no action’. Data on marriage trends in more 
urban environments is not available. The marriage data used in this model does not account 
for the probability that a divorced woman may remarry.
Not all women considering OC for fertility preservation will insist on marriage prior to 
attempting conception. 6.5% of individuals in their thirties and 4.4% of individuals in their 
forties are in unmarried partner unions (26). In 2011 40.7% of births were to unmarried 
women- a 22% increase since 1980 (1). About 1 in 5 births to women in their thirties are in 
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unmarried women (27); approximately half of these births are among women cohabitating 
with their partner (28). For such women, Model B, which does not include marriage rates, 
may be more appropriate.
The benefits of OC are more apparent in Model B, when we assume that all women will 
attempt pregnancy, either with a spouse, partner, or donor sperm. In this situation, in women 
age <32, LBR was high (>70%) in both the OC and ‘no action’ groups and the difference 
between decisions was low (<10%). The first age point when OC had a LBR >70% and a 
LBR difference from ‘no action’ was >10% was 32 years. However, at this age, the cost-per 
additional live birth was high ($73,439).
Two previous cost-effectiveness analysis have been performed, both looking at static 
decision and horizon ages. A Markov model created by van Loendersloot et al. compared 
the cost effectiveness of oocyte cryopreservation in 35 year olds deciding between natural 
conception, IVF-T, and IVF-OC and attempting pregnancy at age 40 from a European 
prospective. They found IVF-OC to be more effective than both natural conception and IVF-
T, but at an addition cost of €13,156 per each additional live birth (22). Hirshfeld-Cytron et 
al. in the US compared OC to no action at age 25 followed by attempting pregnancy at age 
40 and found “no action” to be the most cost-effective route. However, they did find an 
increase in LBR in the OC arm (79.2% vs. 71.8%) (23). Neither of these studies accounted 
for marriage or partnering rates.
For the individual patient, a societal cost or cost-per additional live birth has little meaning. 
The cost of action or no action and the probability of success are the most important factors. 
In both models and all decision ages and horizon periods, OC has a larger overall cost to the 
individual than no action, arising from the large initial cost of OC. However, in all scenarios, 
OC does increase the LBR in the future. If the only consideration is maximizing LBR at any 
cost, then OC should be performed prior to age 34. Undergoing OC in the early thirties has a 
larger impact on LBR when delays in attempts to conceive are longer (7 years) and less 
impact when delays in attempts to conceive are shorter (3 or 5 years) (Supplemental Figure 
2).
For single women in their mid- to late thirties, who would consider using donor sperm or 
sperm from a non-spousal partner, OC will significantly increase the probability of a future 
live birth. Although the overall highest probability of live birth after OC is seen at younger 
ages, the largest benefit (versus no action) is seen at the later ages. In fact, in Model B, when 
approaching age forty and considering a 7-year horizon, OC can salvage the possibility of 
procreation with one’s own eggs. If the objective of OC is to maximize the cost-
effectiveness, then OC should be performed at age 35 (Model A) or age 37 (Model B).
Cil et al. recently conducted a meta-analysis of 1805 individual patients from previous 
studies on OC (24). In these studies, excess oocytes were cryopreserved because embryo 
cryopreservation was legally or socially prohibitive to the patient. Similar to the results of 
our decision tree model, the meta-analysis found that OC at age 36 had the highest 
discrimination capacity for live birth. This finding further validates our finding of the largest 
increase of effectiveness of OC at age 35 or 37 depending on model choice.
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Although our study provides a useful tool to counsel patients when discussing the utility and 
timing of OC for fertility preservation it does have limitations. The models in this study 
assumes a 3-, 5-, or 7-year horizon from the time of initial decision about OC. The Horizon 
Ages chosen were arbitrary. OC is a relatively new technology; ASRM has just recently 
considered it to be no longer experimental (10). Data on the average time to use of electively 
cryopreserved oocytes are not available and will unlikely be compiled in the immediate 
future. Additionally, this model assumes women at the decision age are naïve to fertility 
testing; these models are not appropriate for infertile women or women with documented 
decreased ovarian reserve. Decision analysis models rely on the quality of data used to 
determine the base-case variables. In this study the LBR of embryos derived from 
cryopreserved oocytes was assumed to be equivalent to LBR rates of embryos derived from 
IVF at the women’s age at time of OC (8). A previous decision analysis used a lower LBR 
in women attempting pregnancy using cryopreserved oocytes (23). Our estimate may 
overestimate the efficacy of OC. Additionally, data on unassisted pregnancy rates for 
women over age 43 were not available and were projected using a model. Also, the CDC 
data for women over 40 may overestimate pregnancy rates, as women with poor ovarian 
reserve may be discouraged from doing IVF. However, we attempted to account for 
potential variance in all of the base-case probability measures by performing one-way 
sensitivity analyses.
There are many strengths to this decision model. First it evaluates the utility of OC for a 
wide range of decision ages. In addition, it uses base-case data from large, nationally 
representative data sets. Access to these databases allowed the use patient level data. 
Previous analytic models have relied on results from meta-analyses. Data on natural 
conception rates were derived from a prospective, time-to-pregnancy cohort study of US 
women of older reproductive ages. Previous studies have lacked such data. Numerous 
factors are considered in the model, mimicking “real life” scenarios. Finally, the inclusion of 
data on marriage trends make the results more generalizable.
The results from these models can be used as a tool for physicians providing fertility 
preservation counseling to their patients. An online calculator using data from this model 
has been made available to both patients and physicians at www.UNCfertility.com/egg-
banking-calculator. These models allow the woman to determine her individual probability 
of having a biologic child with or without oocyte cryopreservation, aiding in her decision as 
to whether and when to cryopreserve oocytes. OC is a potentially useful tool for the properly 
selected patient, although at a high cost per additional live birth.
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Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Simplified decision tree for Model A
For a simplified representation of the decision tree, chance nodes for probability of 2nd and 
3rd cycles from frozen oocytes, 1st and 2nd FET, and miscarriage were not shown. Analysis 
was repeated for Decision Age between 25 and 40 years, assuming a 7-year time horizon 
before attempting pregnancy. In Model A (requires marriage to attempt conception), those 
who did not marry did not attempt pregnancy. In Model B, all women attempt pregnancy, 
either with a partner or with donor sperm.
■Denotes decision node
○Denotes chance node
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The Y-axis represents the probability of live birth at Horizon Age, which is 7 years after 
Decision Age. Decision Age is presented on the X-axis. Solid line: cryopreserving oocytes 
(OC). Dashed line: no action. Model A represents women requiring marriage prior to 
attempting pregnancy. Model B represents women who do not require marriage prior to 
attempting pregnancy (will attempt pregnancy with husband, donor sperm, or unmarried 
male partner).
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Cost per additional live birth at Horizon Age when electing to cryopreserve oocytes versus 
no action at Decision Age, which is presented on the X-axis. Model A represents women 
requiring marriage prior to attempting pregnancy. Model B represents women who do not 
require marriage prior to attempting pregnancy (will attempt pregnancy with husband, donor 
sperm or unmarried male partner).
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Table 1
Base-case cost and probability
Cost Estimates (USD)
Service Base Case Low High Citation
Fresh IVF cycle 13273 7183 28739 17–20
Frozen embryo transfer 4169 3275 13107 17–20
Oocyte cryopreservation cycle 9261 4631 13891 Internal cost
Oocyte warming, ICSI, and embryo culture 4416 2208 6624 Internal cost




Natural conception in 6 months "Time to Conceive" study
Miscarriage rate 14
IVF-T live-birth rate 15
IVF-OC live birth rate 15
Supernumerary embryos for 1st and 2nd FET IntegraMed database
Supernumerary oocytes for 2nd and 3rd transfer IntegraMed database
IVF-T - Traditional IVF in no OC group, IVF-OC - IVF in oocyte cryopreservation group, FET- Frozen embryo transfer
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